Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients: A biochemical analysis

American Journal of Pathology

Volumn 169, Issue 3, 2006, Pages 1048-1063

  Patton, R Lyle ^a   Kalback, Walter M ^a   Esh, Chera L ^a   Kokjohn, Tyler A ^a,b   Van Vickle, Gregory D ^a   Luehrs, Dean C ^c   Kuo, Yu Min ^a   Lopez, John ^d   Brune, Daniel ^d   Ferrer, Isidro ^e   Masliah, Eliezer ^f   Newel, Amanda J ^a   Beach, Thomas G ^a   Castaño, Eduardo M ^g   Roher, Alex E ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d ARIZONA STATE UNIVERSITY   (United States)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CLINICAL FEATURE; GRAY MATTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MENINGOENCEPHALITIS; MORPHOLOGY; PRIORITY JOURNAL; WHITE MATTER;

EID: 33748767945     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060269     Document Type: Article

References (73)

1. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342
2. Schenk D, Hagen M, Seubert P: Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004, 16:599-606
3. Solomon B: Alzheimer's disease and immunotherapy. Curr Alzheimer Res 2004, 1:149-163
4. Gelinas DS, Dasilva K, Fenili D, George-Hyslop P, McLaurin J: Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14657-14662
5. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR: Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004, 165:283-297
6. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54
7. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562
8. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M: Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572
9. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, deq Uervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554
10. Weksler ME, Gouras G, Relkin NR, Szabo P: The immune system, amyloid-beta peptide, and Alzheimer's disease. Immunol Rev 2005, 205:244-256
11. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nolker C, Moller HJ, Wei X, Farlow M, Sommer N, Oertel WH: Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474
12. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448-452
13. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004, 14:11-20
14. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131
15. Braak H, Braak E: Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991, 1:213-216
16. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ: The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839
17. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR: Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996, 271:20631-20635
18. Esh C, Patton L, Kalback W, Kokjohn TA, Lopez J, Brune D, Newell AJ, Beach T, Schenk D, Games D, Paul S, Bales K, Ghetti B, Castano EM, Roher AE: Altered APP processing in PDAPP (Val717→Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry 2005, 44:13807-13819
19. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, Ball MJ: Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 1994, 269:10987-10990
20. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ: Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:10836-10840
21. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ: Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993, 268:3072-3083
22. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE: Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptides from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 1997, 237:188-191
23. Boche D, Barton E, Neal J, Ferrer I, Wilkinson D, Bayer A, Holmes C, Weller RO, Nicoll JAR: Effects of Abeta immunotherapy on cerebral amyloid angiopathy in human Alzheimer's disease. Abstracts of the 107th meeting of the British Neuropathological Society. Neuropathol Appl Neurobiol 2006, 32(Suppl 1):3-4
24. Roher AE, Palmer KC, Chau V, Ball MJ: Isolation and chemical characterization of Alzheimer's disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein. J Cell Biol 1988, 107:2703-2716
25. Lowenson JD, Clarke S, Roher AE: Chemical modification of deposited amyloid-β peptides. Methods Enzymol 1999, 309:89-105
26. Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T: Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch Biochem Biophys 2000, 381:225-234
27. Watson D, Castano E, Kokjohn TA, Kuo YM, Lyubchenko Y, Pinsky D, Connolly ES Jr, Esh C, Luehrs DC, Stine WB, Rowse LM, Emmerling MR, Roher AE: Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res 2005, 27:869-881
28. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA: Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci 2004, 1019:1-4
29. Brazil MI, Chung H, Maxfield FR: Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J Biol Chem 2000, 275:16941-16947
30. Chung H, Brazil MI, Soe TT, Maxfield FR: Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells. J Biol Chem 1999, 274:32301-32308
31. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, Roher AE: The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 1998, 273:29719-29726
32. Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo LM, Roher AE: Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 1996, 16:6021-6037
33. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84
34. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM: Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688
35. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE: Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta 1998, 1406:291-298
36. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982
37. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5:452-457
38. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002, 22:6331-6335
39. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T: An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004, 24:6277-6282
40. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M: Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996, 380:168-171
41. Crawford F, Suo Z, Fang C, Sawar A, Su G, Arendash G, Mullan M: The vasoactivity of Aβ peptides. Ann NY Acad Sci 1997, 826:35-46
42. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti S, Mullan M: Inhibition of angiogenesis by Aβ peptides. Angiogenesis 2004, 7:75-85
43. Paris D, Town T, Parker T, Humphrey J, Mullan M: Aβ vasoactivity: an inflammatory reaction. Ann NY Acad Sci 2000, 903:97-109
44. Iadecola C: Cerebrovascular effects of amyloid-β peptides: mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol 2003, 23:681-689
45. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002, 298:1379
46. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005, 25:629-636
47. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM, Roher AE: Cerebral amyloid angiopathy: amyloid-p accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998, 153:725-733
48. Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO: Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 2003, 29:106-117
49. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Childress JL, Beach TG, Weller RO, Kokjohn TA: Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 2003, 9:112-122
50. Weller RO, Cohen NR, Nicoll JA: Cerebrovascular disease and the pathophysiology of Alzheimer's disease: implications for therapy. Panminerva Med 2004, 46:239-251
51. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ: Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005, 11:556-561
52. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004, 1:24
53. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE: The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 2001, 7:609-618
54. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE: Elevated Aβ and apolipoprotein E in AβPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 2000, 6:430-439
55. Higgins LS, Murphy GM Jr, Forno LS, Catalano R, Cordell B: P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol 1996, 149:585-596
56. Wei W, Norton DD, Wang X, Kusiak JW: Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 2002, 125:2036-2043
57. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS: Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc Nat Acad Sci USA 2001, 98:14675-14680
58. Pillot T, Goethals M, Vanloo B, Talussot C, Brasseur R, Vandekerckhove J, Rosseneu M, Lins L: Fusogenic properties of the C-terminal domain of the Alzheimer β-amyloid peptide. J Biol Chem 1996, 271:28757-28765
59. McLaurin J, Chakrabartty A: Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides: implications for neurotoxicity. J Biol Chem 1996, 271:26482-26489
60. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG: Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005, 280:17294-17300
61. Marchesi VT: An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer's disease. Proc Natl Acad Sci USA 2005, 102:9093-9098
62. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P: Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005, 58:430-435
63. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D: Intracranial administration of deglycosylated modified C-terminal-specific anti-A antibody efficiently clears amyloid plaques without activating microglia in amyloid depositing transgenic mice. J Neuroinflammation 2006, 3:11
64. Roher AE, Weiss N, Kokjohn TA, Kuo Y: M., Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T: Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002, 41:11080-11090
65. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 1997, 18:415-421
66. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S, Hsu CY: Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 2004, 164:123-131
67. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG: Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 2003, 14:1429-1433
68. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO: Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease: pro-CAA position statement. Neurobiol Aging 2004, 25:589-597
69. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE: Anti-Abeta(42)- and anti-Abeta(40)-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006, 116:193-201
70. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE: Reduced effectiveness of Aβ 1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001, 22:721-727
71. Zhou J, Fonseca MI, Kayed R, Hernandez I, Webster SD, Yazan O, Cribbs DH, Glabe CG, Tenner AJ: Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation 2005, 2:28
72. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR: Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med 2005, 2:e355
73. Chaney MO, Webster SD, Kuo YM, Roher AE: Molecular modeling of the Aβ-42 peptide from Alzheimer's disease. Protein Eng 1998, 11:761-767